APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostaglandin E2 Receptor EP4 Subtype

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Prostaglandin E2 Receptor EP4 Subtype Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchProstaglandin E2 Receptor EP4 Subtype Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostaglandin E2 Receptor EP4 Subtype Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Prostaglandin E2 Receptor EP4 Subtype Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostaglandin E2 Receptor EP4 Subtype Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostaglandin E2 Receptor EP4 Subtype Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Prostaglandin E2 Receptor EP4 Subtype market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Prostaglandin E2 Receptor EP4 Subtype is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prostaglandin E2 Receptor EP4 Subtype is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prostaglandin E2 Receptor EP4 Subtype is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Prostaglandin E2 Receptor EP4 Subtype market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Prostaglandin E2 Receptor EP4 Subtype market include Eisai Co Ltd, Eli Lilly and Co, Rottapharm Biotech Srl, RaQualia Pharma Inc, Ono Pharmaceutical Co Ltd and Kaken Pharmaceutical Co Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Prostaglandin E2 Receptor EP4 Subtype market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostaglandin E2 Receptor EP4 Subtype and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostaglandin E2 Receptor EP4 Subtype revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Prostaglandin E2 Receptor EP4 Subtype market.

Prostaglandin E2 Receptor EP4 Subtype Segment by Company

Eisai Co Ltd

Eli Lilly and Co

Rottapharm Biotech Srl

RaQualia Pharma Inc

Ono Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Prostaglandin E2 Receptor EP4 Subtype Segment by Type

ONO-4232

KAG-308

ER-886046

Grapiprant

E-7046

Others

Prostaglandin E2 Receptor EP4 Subtype Segment by Application

Breast Cancer

Chronic Pain

Acute Pain

Allergies

Lung Cancer

Others

Prostaglandin E2 Receptor EP4 Subtype Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Prostaglandin E2 Receptor EP4 Subtype status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Prostaglandin E2 Receptor EP4 Subtype key companies, revenue, market share, and recent developments.

3. To split the Prostaglandin E2 Receptor EP4 Subtype breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Prostaglandin E2 Receptor EP4 Subtype market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prostaglandin E2 Receptor EP4 Subtype significant trends, drivers, influence factors in global and regions.

6. To analyze Prostaglandin E2 Receptor EP4 Subtype competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostaglandin E2 Receptor EP4 Subtype market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostaglandin E2 Receptor EP4 Subtype and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostaglandin E2 Receptor EP4 Subtype.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostaglandin E2 Receptor EP4 Subtype industry.

Chapter 3: Detailed analysis of Prostaglandin E2 Receptor EP4 Subtype company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Prostaglandin E2 Receptor EP4 Subtype in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Prostaglandin E2 Receptor EP4 Subtype in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prostaglandin E2 Receptor EP4 Subtype Industry Trends Table 2. Prostaglandin E2 Receptor EP4 Subtype Industry Drivers Table 3. Prostaglandin E2 Receptor EP4 Subtype Industry Opportunities and Challenges Table 4. Prostaglandin E2 Receptor EP4 Subtype Industry Restraints Table 5. Global Prostaglandin E2 Receptor EP4 Subtype Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prostaglandin E2 Receptor EP4 Subtype Revenue Share by Company (2021-2026) Table 7. Global Prostaglandin E2 Receptor EP4 Subtype Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Prostaglandin E2 Receptor EP4 Subtype Key Company Manufacturing Base & Headquarters Table 9. Global Prostaglandin E2 Receptor EP4 Subtype Company, Product Type & Application Table 10. Global Prostaglandin E2 Receptor EP4 Subtype Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Prostaglandin E2 Receptor EP4 Subtype by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of ONO-4232 Table 15. Significant Companies of KAG-308 Table 16. Significant Companies of ER-886046 Table 17. Significant Companies of Grapiprant Table 18. Significant Companies of E-7046 Table 19. Significant Companies of Others Table 20. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type (2021-2026) Table 24. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Breast Cancer Table 26. Significant Companies of Chronic Pain Table 27. Significant Companies of Acute Pain Table 28. Significant Companies of Allergies Table 29. Significant Companies of Lung Cancer Table 30. Significant Companies of Others Table 31. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application (2021-2026) Table 35. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application (2027-2032) Table 36. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Region (2021-2026) Table 39. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Region (2027-2032) Table 41. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Market Share by Country (2021-2026) Table 44. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Market Share by Country (2027-2032) Table 46. Eisai Co Ltd Company Information Table 47. Eisai Co Ltd Business Overview Table 48. Eisai Co Ltd Prostaglandin E2 Receptor EP4 Subtype Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Eisai Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio Table 50. Eisai Co Ltd Recent Development Table 51. Eli Lilly and Co Company Information Table 52. Eli Lilly and Co Business Overview Table 53. Eli Lilly and Co Prostaglandin E2 Receptor EP4 Subtype Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Eli Lilly and Co Prostaglandin E2 Receptor EP4 Subtype Product Portfolio Table 55. Eli Lilly and Co Recent Development Table 56. Rottapharm Biotech Srl Company Information Table 57. Rottapharm Biotech Srl Business Overview Table 58. Rottapharm Biotech Srl Prostaglandin E2 Receptor EP4 Subtype Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Rottapharm Biotech Srl Prostaglandin E2 Receptor EP4 Subtype Product Portfolio Table 60. Rottapharm Biotech Srl Recent Development Table 61. RaQualia Pharma Inc Company Information Table 62. RaQualia Pharma Inc Business Overview Table 63. RaQualia Pharma Inc Prostaglandin E2 Receptor EP4 Subtype Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. RaQualia Pharma Inc Prostaglandin E2 Receptor EP4 Subtype Product Portfolio Table 65. RaQualia Pharma Inc Recent Development Table 66. Ono Pharmaceutical Co Ltd Company Information Table 67. Ono Pharmaceutical Co Ltd Business Overview Table 68. Ono Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Ono Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio Table 70. Ono Pharmaceutical Co Ltd Recent Development Table 71. Kaken Pharmaceutical Co Ltd Company Information Table 72. Kaken Pharmaceutical Co Ltd Business Overview Table 73. Kaken Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Kaken Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio Table 75. Kaken Pharmaceutical Co Ltd Recent Development Table 76. Research Programs/Design for This Report Table 77. Authors List of This Report Table 78. Secondary Sources Table 79. Primary Sources List of Figures Figure 1. Prostaglandin E2 Receptor EP4 Subtype Product Image Figure 2. Global Prostaglandin E2 Receptor EP4 Subtype Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostaglandin E2 Receptor EP4 Subtype Market Size (2021-2032) & (US$ Million) Figure 4. Global Prostaglandin E2 Receptor EP4 Subtype Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. ONO-4232 Image Figure 8. KAG-308 Image Figure 9. ER-886046 Image Figure 10. Grapiprant Image Figure 11. E-7046 Image Figure 12. Others Image Figure 13. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type (2021-2032) Figure 16. Breast Cancer Image Figure 17. Chronic Pain Image Figure 18. Acute Pain Image Figure 19. Allergies Image Figure 20. Lung Cancer Image Figure 21. Others Image Figure 22. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application (2021-2032) Figure 25. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032) & (US$ Million) Figure 28. North America Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032) & (US$ Million) Figure 30. Europe Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032) & (US$ Million) Figure 34. South America Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • ONO-4232
  • KAG-308
  • ER-886046
  • Grapiprant
  • E-7046
  • Others
Applications
  • Breast Cancer
  • Chronic Pain
  • Acute Pain
  • Allergies
  • Lung Cancer
  • Others
Companies covered
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Rottapharm Biotech Srl
  • RaQualia Pharma Inc
  • Ono Pharmaceutical Co Ltd
  • Kaken Pharmaceutical Co Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Prostaglandin E2 Receptor EP4 Subtype Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Prostaglandin E2 Receptor EP4 Subtype Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Prostaglandin E2 Receptor EP4 Subtype Market Dynamics
  1. 2.1 Prostaglandin E2 Receptor EP4 Subtype Industry Trends
  2. 2.2 Prostaglandin E2 Receptor EP4 Subtype Industry Drivers
  3. 2.3 Prostaglandin E2 Receptor EP4 Subtype Industry Opportunities and Challenges
  4. 2.4 Prostaglandin E2 Receptor EP4 Subtype Industry Restraints
3 Prostaglandin E2 Receptor EP4 Subtype Market by Company
  1. 3.1 Global Prostaglandin E2 Receptor EP4 Subtype Company Revenue Ranking in 2025
  2. 3.2 Global Prostaglandin E2 Receptor EP4 Subtype Revenue by Company (2021-2026)
  3. 3.3 Global Prostaglandin E2 Receptor EP4 Subtype Company Ranking (2024-2026)
  4. 3.4 Global Prostaglandin E2 Receptor EP4 Subtype Company Manufacturing Base and Headquarters
  5. 3.5 Global Prostaglandin E2 Receptor EP4 Subtype Company Product Type and Application
  6. 3.6 Global Prostaglandin E2 Receptor EP4 Subtype Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Prostaglandin E2 Receptor EP4 Subtype Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Prostaglandin E2 Receptor EP4 Subtype Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Prostaglandin E2 Receptor EP4 Subtype Market by Type
  1. 4.1 Prostaglandin E2 Receptor EP4 Subtype Type Introduction
  2. 4.1.1 ONO-4232
  3. 4.1.2 KAG-308
  4. 4.1.3 ER-886046
  5. 4.1.4 Grapiprant
  6. 4.1.5 E-7046
  7. 4.1.6 Others
  8. 4.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Type
  9. 4.2.1 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Type (2021-2032)
  11. 4.2.3 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type (2021-2032)
5 Prostaglandin E2 Receptor EP4 Subtype Market by Application
  1. 5.1 Prostaglandin E2 Receptor EP4 Subtype Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Chronic Pain
  4. 5.1.3 Acute Pain
  5. 5.1.4 Allergies
  6. 5.1.5 Lung Cancer
  7. 5.1.6 Others
  8. 5.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Application
  9. 5.2.1 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Application (2021-2032)
  11. 5.2.3 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application (2021-2032)
6 Prostaglandin E2 Receptor EP4 Subtype Regional Value Analysis
  1. 6.1 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Region (2021-2032)
  3. 6.2.1 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Region: 2021-2026
  4. 6.2.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032)
  7. 6.3.2 North America Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032)
  10. 6.4.2 Europe Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032)
  16. 6.6.2 South America Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Country, 2025 VS 2032
7 Prostaglandin E2 Receptor EP4 Subtype Country-level Value Analysis
  1. 7.1 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Country (2021-2032)
  3. 7.2.1 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Country (2021-2026)
  4. 7.2.2 Global Prostaglandin E2 Receptor EP4 Subtype Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Prostaglandin E2 Receptor EP4 Subtype Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Prostaglandin E2 Receptor EP4 Subtype Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai Co Ltd
  2. 8.1.1 Eisai Co Ltd Company Information
  3. 8.1.2 Eisai Co Ltd Business Overview
  4. 8.1.3 Eisai Co Ltd Prostaglandin E2 Receptor EP4 Subtype Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
  6. 8.1.5 Eisai Co Ltd Recent Developments
  7. 8.2 Eli Lilly and Co
  8. 8.2.1 Eli Lilly and Co Company Information
  9. 8.2.2 Eli Lilly and Co Business Overview
  10. 8.2.3 Eli Lilly and Co Prostaglandin E2 Receptor EP4 Subtype Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Co Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
  12. 8.2.5 Eli Lilly and Co Recent Developments
  13. 8.3 Rottapharm Biotech Srl
  14. 8.3.1 Rottapharm Biotech Srl Company Information
  15. 8.3.2 Rottapharm Biotech Srl Business Overview
  16. 8.3.3 Rottapharm Biotech Srl Prostaglandin E2 Receptor EP4 Subtype Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Rottapharm Biotech Srl Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
  18. 8.3.5 Rottapharm Biotech Srl Recent Developments
  19. 8.4 RaQualia Pharma Inc
  20. 8.4.1 RaQualia Pharma Inc Company Information
  21. 8.4.2 RaQualia Pharma Inc Business Overview
  22. 8.4.3 RaQualia Pharma Inc Prostaglandin E2 Receptor EP4 Subtype Revenue and Gross Margin (2021-2026)
  23. 8.4.4 RaQualia Pharma Inc Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
  24. 8.4.5 RaQualia Pharma Inc Recent Developments
  25. 8.5 Ono Pharmaceutical Co Ltd
  26. 8.5.1 Ono Pharmaceutical Co Ltd Company Information
  27. 8.5.2 Ono Pharmaceutical Co Ltd Business Overview
  28. 8.5.3 Ono Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ono Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
  30. 8.5.5 Ono Pharmaceutical Co Ltd Recent Developments
  31. 8.6 Kaken Pharmaceutical Co Ltd
  32. 8.6.1 Kaken Pharmaceutical Co Ltd Company Information
  33. 8.6.2 Kaken Pharmaceutical Co Ltd Business Overview
  34. 8.6.3 Kaken Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Kaken Pharmaceutical Co Ltd Prostaglandin E2 Receptor EP4 Subtype Product Portfolio
  36. 8.6.5 Kaken Pharmaceutical Co Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst